The regulation of human hepatic drug transporter expression by activation of xenobiotic-sensing nuclear receptors

References

• Liang Y, Li S, Chen L. The physiological role of drug transporters. Protein Cell. 2015;6(5):334–350.
   PubMed Web of Science ®Google Scholar
• Hediger MA, Clémençon B, Burrier RE, et al. The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol Aspects Med. 2013;34(2–3):95–107.
   PubMed Web of Science ®Google Scholar
• Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001;11(7):1156–1166.
   PubMed Web of Science ®Google Scholar
• Döring B, Petzinger E. Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism. Drug Metab Rev. 2014;46(3):261–282.
   PubMed Web of Science ®Google Scholar
• Lai Y, Hsiao P. Beyond the ITC white paper: emerging sciences in drug transporters and opportunities for drug development. Curr Pharm Des. 2014;20(10):1577–1594.
   PubMed Web of Science ®Google Scholar
• Hillgren KM, Keppler D, Zur AA, et al.; International Transporter Consortium, Emerging transporters of clinical importance: an update from the international transporter consortium. Clin Pharmacol Ther 2013;94(1):52–63.
   PubMed Web of Science ®Google Scholar
• Chu X, Korzekwa K, Elsby R, et al. Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver. Clin Pharmacol Ther. 2013;94(1):126–141.
   PubMed Web of Science ®Google Scholar
• Yu J, Ritchie TK, Zhou Z, et al. Key findings from preclinical and clinical drug interaction studies presented in new drug and biological license Applications approved by the food and drug administration in 2014. Drug Metab Dispos. 2016;44(1):83–101.
   PubMed Web of Science ®Google Scholar
• Tirona RG. Molecular mechanisms of drug transporter regulation. Handb Exp Pharmacol. 2011;201:373–402.
   PubMedGoogle Scholar
• König J, Müller F, Fromm MF. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev. 2013;65(3):944–966.
   PubMed Web of Science ®Google Scholar
• FDA U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry, drug interaction studies—study design, data analysis, implications for dosing, and labeling recommendations. Feb 2012 [cited 2015 Dec 23] Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf.
   Google Scholar
• European Medicines Agency (EMA). Guideline on the investigation of drug interactions. 2012 cited 2016 Jan 19]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf.
   Google Scholar
• Schupp M, Lazar MA. Endogenous ligands for nuclear receptors: digging deeper. J Biol Chem. 2010;285(52):40409–40415.
   PubMed Web of Science ®Google Scholar
• Chai X, Zeng S, Xie W. Nuclear receptors PXR and CAR: implications for drug metabolism regulation, pharmacogenomics and beyond. Expert Opin Drug Metab Toxicol. 2013;9:253–266.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Mani S. Orphan nuclear receptors as targets for drug development. Pharm Res. 2010;27:1439–1468.
   PubMed Web of Science ®Google Scholar
• Zou A, Lehn S, Magee N, et al. New insights into orphan nuclear receptor SHP in liver cancer. Nucl Receptor Res. 2015;2. pii: 101162. doi:10.1131/2015/101162.
   PubMedGoogle Scholar
• Tolson AH, Wang H. Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev. 2010;62(13):1238–1249.
   PubMed Web of Science ®Google Scholar
• Wang J, Dai S, Guo Y, et al. Biology of PXR: role in drug-hormone interactions. Excli J. 2014;13:728–739. eCollection 2014
   PubMed Web of Science ®Google Scholar
• Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell. 1995;83(6):835–839.
   PubMed Web of Science ®Google Scholar
• Mottino AD, Catania VA. Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents. World J Gastroenterol. 2008;14(46):7068–7074.
   PubMed Web of Science ®Google Scholar
• Hernandez JP, Mota LC, Baldwin WS. Activation of CAR and PXR by dietary, environmental and occupational chemicals alters drug metabolism, intermediary metabolism, and cell proliferation. Curr Pharmacogenomics Person Med. 2009;7(2):81–105.
   PubMedGoogle Scholar
• Lamba JK, Lamba V, Yasuda K, et al. Expression of constitutive androstane receptor splice variants in human tissues and their functional consequences. J Pharmacol Exp Ther. 2004;311(2):811–821.
   PubMed Web of Science ®Google Scholar
• Choi EJ, Jang YJ, Cha EY, et al. Identification and characterization of novel alternative splice variants of human constitutive androstane receptor in liver samples of Koreans and Caucasians. Drug Metab Dispos. 2013;41(4):888–896.
   PubMed Web of Science ®Google Scholar
• Jinno H, Tanaka-Kagawa T, Hanioka N, et al. Identification of novel alternative splice variants of human constitutive androstane receptor and characterization of their expression in the liver. Mol Pharmacol. 2004;65(3):496–502.
   PubMed Web of Science ®Google Scholar
• Omiecinski CJ, Coslo DM, Chen T, et al. Multi-species analyses of direct activators of the constitutive androstane receptor. Toxicol Sci. 2011;123(2):550–562.
   PubMed Web of Science ®Google Scholar
• di Masi A, De Marinis E, Ascenzi P, et al. Nuclear receptors CAR and PXR: molecular, functional, and biomedical aspects. Mol Aspects Med. 2009;30:297–343.
   PubMed Web of Science ®Google Scholar
• Yang H, Wang H. Signaling control of the constitutive androstane receptor (CAR). Protein Cell. 2014;5(2):113–123.
   PubMed Web of Science ®Google Scholar
• Kawamoto T, Sueyoshi T, Zelko I, et al. Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol Cell Biol. 1999;19(9):6318–6322.
   PubMed Web of Science ®Google Scholar
• Mutoh S, Sobhany M, Moore R, et al. Phenobarbital indirectly activates the constitutive active androstane receptor (CAR) by inhibition of epidermal growth factor receptor signaling. Sci Signal. 2013;6(274):ra31.
   PubMed Web of Science ®Google Scholar
• Wada T, Gao J, Xie W. PXR and CAR in energy metabolism. Trends Endocrinol Metab. 2009;20(6):273–279.
   PubMed Web of Science ®Google Scholar
• Li L, Li H, Garzel B, et al. SLC13A5 is a novel transcriptional target of the pregnane X receptor and sensitizes drug-induced steatosis in human liver. Mol Pharmacol. 2015;87(4):674–682.
   PubMed Web of Science ®Google Scholar
• Molnár F, Küblbeck J, Jyrkkärinne J, et al. An update on the constitutive androstane receptor (CAR). Drug Metabol Drug Interact. 2013;28(2):79–93.
   PubMedGoogle Scholar
• Carazo A, Pávek P. The use of the lanthaScreen TR-FRET CAR coactivator assay in the characterization of Constitutive Androstane Receptor (CAR) inverse agonists. Sensors (Basel). 2015;15(4):9265–9276.
   PubMed Web of Science ®Google Scholar
• Zhang J, Kuehl P, Green ED, et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 2001;11(7):555–572.
   PubMedGoogle Scholar
• Koyano S, Kurose K, Saito Y, et al. Functional characterization of four naturally occurring variants of human pregnane X receptor (PXR): one variant causes dramatic loss of both DNA binding activity and the transactivation of the CYP3A4 promoter/enhancer region. Drug Metab Dispos. 2004;32(1):149–154.
   PubMed Web of Science ®Google Scholar
• Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev. 2002;23:687–702.
   PubMed Web of Science ®Google Scholar
• Chang TK. Activation of pregnane X receptor (PXR) and constitutive androstane receptor (CAR) by herbal medicines. AAPS J. 2009;11(3):590–601.
   PubMed Web of Science ®Google Scholar
• Gollamudi R, Gupta D, Goel S, et al. Novel orphan nuclear receptors-coregulator interactions controlling anti-cancer drug metabolism. Curr Drug Metab. 2008;9(7):611–613.
   PubMed Web of Science ®Google Scholar
• Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001;276(18):14581–14587.
   PubMed Web of Science ®Google Scholar
• Teng S, Jekerle V, Piquette-Miller M. Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab Dispos. 2003;31(11):1296–1299.
   PubMed Web of Science ®Google Scholar
• Staudinger J, Liu Y, Madan A, et al. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab Dispos. 2001;29(11):1467–1472.
   PubMed Web of Science ®Google Scholar
• Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol. 2008;1(2):93–105.
   PubMedGoogle Scholar
• Ihunnah CA, Jiang M, Xie W. Nuclear receptor PXR, transcriptional circuits and metabolic relevance. Biochim Biophys Acta. 2011;1812(8):956–963.
   PubMed Web of Science ®Google Scholar
• Iwazaki N, Kobayashi K, Morimoto K, et al. Involvement of hepatocyte nuclear factor 4 alpha in transcriptional regulation of the human pregnane X receptor gene in the human liver. Drug Metab Pharmacokinet. 2008;23(1):59–66.
   PubMed Web of Science ®Google Scholar
• Kamiyama Y, Matsubara T, Yoshinari K, et al. Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. Drug Metab Pharmacokinet. 2007;22(4):287–298.
   PubMed Web of Science ®Google Scholar
• Smutny T, Mani S, Pavek P. Post-translational and post-transcriptional modifications of pregnane X receptor (PXR) in regulation of the cytochrome P450 superfamily. Curr Drug Metab. 2013;14(10):1059–1069.
   PubMed Web of Science ®Google Scholar
• Pondugula SR, Dong H, Chen T. Phosphorylation and protein-protein interactions in PXR-mediated CYP3A repression. Expert Opin Drug Metab Toxicol. 2009;5(8):861–873.
   PubMed Web of Science ®Google Scholar
• Bossis G, Melchior F. SUMO: regulating the regulator. Cell Div. 2006;1:13.
   PubMed Web of Science ®Google Scholar
• Kotiya D, Rana M, Subbarao N, et al. Transcription regulation of nuclear receptor PXR: role of SUMO-1 modification and NDSM in receptor function. Mol Cell Endocrinol. 2016;420:194–207.
   PubMed Web of Science ®Google Scholar
• Staudinger JL, Xu C, Biswas A, et al. Post-translational modification of pregnane x receptor. Pharmacol Res. 2011;64(1):4–10.
   PubMed Web of Science ®Google Scholar
• Wang YM, Ong SS, Chai SC, et al. Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin Drug Metab Toxicol. 2012;8(7):803–817.
   PubMed Web of Science ®Google Scholar
• Timsit YE, Negishi M. Coordinated regulation of nuclear receptor CAR by CCRP/DNAJC7, HSP70 and the ubiquitin-proteasome system. PLoS One. 2014;9(5):e96092.
   Google Scholar
• Sugatani J, Hattori Y, Noguchi Y, et al. Threonine-290 regulates nuclear translocation of the human pregnane X receptor through its phosphorylation/dephosphorylation by Ca2+/calmodulin-dependent protein kinase II and protein phosphatase 1. Drug Metab Dispos. 2014;42(10):1708–1718.
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Yamagami S, Higuchi T, et al. Key structural features of ligands for activation of human pregnane X receptor. Drug Metab Dispos. 2004;32(4):468–472.
   PubMed Web of Science ®Google Scholar
• Kliewer SA. The nuclear pregnane X receptor regulates xenobiotic detoxification. J Nutr. 2003;133(7 Suppl):2444S–2447S.
   PubMed Web of Science ®Google Scholar
• Moore LB, Parks DJ, Jones SA, et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem. 2000;275:15122–15127.
   PubMed Web of Science ®Google Scholar
• Choi HS, Chung M, Tzameli I, et al. Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR. J Biol Chem. 1997;272(38):23565–23571.
   PubMed Web of Science ®Google Scholar
• Chu V, Einolf HJ, Evers R, et al. In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective. Drug Metab Dispos. 2009;37(7):1339–1354.
   PubMed Web of Science ®Google Scholar
• Scheer N, Roland Wolf C. Xenobiotic receptor humanized mice and their utility. Drug Metab Rev. 2013;45(1):110–121.
   PubMed Web of Science ®Google Scholar
• Ross J, Plummer SM, Rode A, et al. Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogens phenobarbital and chlordane in vivo. Toxicol Sci. 2010;116:452–466.
   PubMed Web of Science ®Google Scholar
• LeCluyse EL. Pregnane X receptor: molecular basis for species differences in CYP3A induction by xenobiotics. Chem Biol Interact. 2001;134(3):283–289.
   PubMed Web of Science ®Google Scholar
• Jones SA, Moore LB, Shenk JL, et al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol. 2000;14(1):27–39.
   PubMed Web of Science ®Google Scholar
• Baker M. Tissue models: a living system on a chip. Nature. 2011;471(7340):661–665.
   PubMed Web of Science ®Google Scholar
• Chan CY, Huang PH, Guo F, et al. Accelerating drug discovery via organs-on-chips. Lab Chip. 2013;13(24):4697–4710.
   PubMed Web of Science ®Google Scholar
• Dai G, Wan YJ. Animal models of xenobiotic receptors. Curr Drug Metab. 2005;6(4):341–355.
   PubMed Web of Science ®Google Scholar
• Lundquist P, Lööf J, Sohlenius-Sternbeck AK, et al. The impact of solute carrier (SLC) drug uptake transporter loss in human and rat cryopreserved hepatocytes on clearance predictions. Drug Metab Dispos. 2014a;42(3):469–480.
   PubMed Web of Science ®Google Scholar
• Lundquist P, Englund G, Skogastierna C, et al. Functional ATP-binding cassette drug efflux transporters in isolated human and rat hepatocytes significantly affect assessment of drug disposition. Drug Metab Dispos. 2014b;42(3):448–458.
   PubMed Web of Science ®Google Scholar
• Jigorel E, Le Vee M, Boursier-Neyret C, et al. Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos. 2006;34(10):1756–1763.
   PubMed Web of Science ®Google Scholar
• Gu X, Manautou JE. Regulation of hepatic ABCC transporters by xenobiotics and in disease states. Drug Metab Rev. 2010;42(3):482–538.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, International Transporter Consortium, Huang SM, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215–236.
   PubMed Web of Science ®Google Scholar
• Kunze A, Huwyler J, Camenisch G, et al. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data. Drug Metab Dispos. 2014;42(9):1514–1521.
   PubMed Web of Science ®Google Scholar
• Tarling EJ, de Aguiar Vallim TQ, Edwards PA. Role of ABC transporters in lipid transport and human disease. Trends Endocrinol Metab. 2013;24(7):342–350.
   PubMed Web of Science ®Google Scholar
• Gong IY, Kim RB. Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet. 2013;28(1):4–18.
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Stieger B. The SLCO (former SLC21) superfamily of transporters. Mol Aspects Med. 2013;34(2–3):396–412.
   PubMed Web of Science ®Google Scholar
• Alexander SP, Benson HE, Faccenda E, et al. The concise guide to PHARMACOLOGY 2013/14: transporters. Br J Pharmacol. 2013;170(8):1706–1796.
   PubMed Web of Science ®Google Scholar
• Zhang L, Strong JM, Qiu W, et al. Scientific perspectives on drug transporters and their role in drug interactions. Mol Pharm. 2006;3(1):62–69.
   PubMed Web of Science ®Google Scholar
• van Montfoort JE, Hagenbuch B, Groothuis GM, et al. Drug uptake systems in liver and kidney. Curr Drug Metab. 2003;4(3):185–211.
   PubMed Web of Science ®Google Scholar
• Svoboda M, Riha J, Wlcek K, et al. Organic anion transporting polypeptides (OATPs): regulation of expression and function. Curr Drug Metab. 2011;12(2):139–153.
   PubMed Web of Science ®Google Scholar
• Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 2012;165:1260–1287.
   PubMed Web of Science ®Google Scholar
• Pfennig T, Herrmann B, Bauer T, et al. Benzoic acid and specific 2-oxo acids activate hepatic efflux of glutamate at OAT2. Biochim Biophys Acta. 2013;1828(2):491–498.
   PubMed Web of Science ®Google Scholar
• Gozalpour E, Greupink R, Wortelboer HM, et al. Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3. Mol Pharm. 2014;11(6):1844–1855.
   PubMed Web of Science ®Google Scholar
• Maeda K, Ikeda Y, Fujita T, et al. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther. 2011;90(4):575–581.
   PubMed Web of Science ®Google Scholar
• Varma MV, Lai Y, Kimoto E, et al. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Pharm Res. 2013;30(4):1188–1199.
   PubMed Web of Science ®Google Scholar
• Varma MV, Scialis RJ, Lin J, et al. Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. AAPS J. 2014;16(4):736–748.
   PubMed Web of Science ®Google Scholar
• Vildhede A, Karlgren M, Svedberg EK, et al. Hepatic uptake of atorvastatin: influence of variability in transporter expression on uptake clearance and drug-drug interactions. Drug Metab Dispos. 2014;42(7):1210–1218.
   Google Scholar
• Badée J, Achour B, Rostami-Hodjegan A, et al. Meta-analysis of expression of hepatic organic anion-transporting polypeptide (OATP) transporters in cellular systems relative to human liver tissue. Drug Metab Dispos. 2015;43(4):424–432.
   PubMed Web of Science ®Google Scholar
• Chen L, Hong C, Chen EC, et al. Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3. Pharmacogenomics J. 2013;13(2):110–120.
   PubMed Web of Science ®Google Scholar
• Nies AT, Niemi M, Burk O, et al. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med. 2013;5(1):1.
   PubMed Web of Science ®Google Scholar
• FDA drug development and drug interactions: table of substrates, inhibitors and inducers. [cited 2015 Dec 23]. Available from: http //www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm.
   Google Scholar
• Staudinger JL, Woody S, Sun M, et al. Nuclear-receptor-mediated regulation of drug- and bile-acid-transporter proteins in gut and liver. Drug Metab Rev. 2013 Feb;45(1):48–59.
   PubMed Web of Science ®Google Scholar
• Meyer Z, Schwabedissen HE, Böttcher K, et al. Liver X receptor α and farnesoid X receptor are major transcriptional regulators of OATP1B1. Hepatology. 2010;52(5):1797–1807.
   PubMed Web of Science ®Google Scholar
• Knauer MJ, Girdwood AJ, Kim RB, et al. Transport function and transcriptional regulation of a liver-enriched human organic anion transporting polypeptide 2B1 transcriptional start site variant. Mol Pharmacol. 2013;83(6):1218–1228.
   PubMed Web of Science ®Google Scholar
• Rulcova A, Krausova L, Smutny T, et al. Glucocorticoid receptor regulates organic cation transporter 1 (OCT1, SLC22A1) expression via HNF4α upregulation in primary human hepatocytes. Pharmacol Rep. 2013;65(5):1322–1335.
   PubMed Web of Science ®Google Scholar
• Hyrsova L, Smutny T, Carazo A, et al. The pregnane X receptor down-regulates organic cation transporter 1 (SLC22A1) in human hepatocytes by squelching SRC-1 coactivator. Br J Pharmacol. 2016 Feb 27. [Epub ahead of print]. doi:10.1111/bph.13472.
   PubMed Web of Science ®Google Scholar
• O’Brien VP, Bokelmann K, Ramírez J, et al. Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene. J Pharmacol Exp Ther. 2013 Oct;347(1):181–192.
   PubMed Web of Science ®Google Scholar
• Tamai I. Pharmacological and pathophysiological roles of carnitine/organic cation transporters (OCTNs: SLC22A4, SLC22A5 and Slc22a21). Biopharm Drug Dispos. 2013;34(1):29–44.
   PubMed Web of Science ®Google Scholar
• Luo H, Zhang Y, Guo H, et al. Transcriptional regulation of the human, porcine and bovine OCTN2 gene by PPARα via a conserved PPRE located in intron 1. BMC Genet. 2014;15:90.
   PubMed Web of Science ®Google Scholar
• Eder K, Ringseis R. The role of peroxisome proliferator-activated receptor alpha in transcriptional regulation of novel organic cation transporters. Eur J Pharmacol. 2010;628(1–3):1–5.
   PubMed Web of Science ®Google Scholar
• Popowski K, Eloranta JJ, Saborowski M, et al. The human organic anion transporter 2 gene is transactivated by hepatocyte nuclear factor-4 alpha and suppressed by bile acids. Mol Pharmacol. 2005;67(5):1629–1638.
   PubMed Web of Science ®Google Scholar
• Denson LA, Sturm E, Echevarria W, et al. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. Gastroenterology. 2001;121(1):140–147.
   PubMed Web of Science ®Google Scholar
• Eloranta JJ, Jung D, Kullak-Ublick GA. The human Na+-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanism. Mol Endocrinol. 2006;20(1):65–79.
   PubMed Web of Science ®Google Scholar
• Rizzo G, Renga B, Mencarelli A, et al. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5(3):289–303.
   PubMedGoogle Scholar
• Jung D, Hagenbuch B, Fried M, et al. Role of liver-enriched transcription factors and nuclear receptors in regulating the human, mouse, and rat NTCP gene. Am J Physiol Gastrointest Liver Physiol. 2004;286(5):G752–61.
   Google Scholar
• Klaassen CD, Slitt AL. Regulation of hepatic transporters by xenobiotic receptors. Curr Drug Metab. 2005;6(4):309–328.
   PubMed Web of Science ®Google Scholar
• Kajiwara M, Terada T, Asaka J, et al. Critical roles of Sp1 in gene expression of human and rat H+/organic cation antiporter MATE1. Am J Physiol Renal Physiol. 2007;293(5):F1564–70.
   Google Scholar
• Lickteig AJ, Cheng X, Augustine LM, et al. Tissue distribution, ontogeny and induction of the transporters multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in mice. Life Sci. 2008 Jul 4;83(1–2):59–64.
   PubMed Web of Science ®Google Scholar
• Wilkens S. Structure and mechanism of ABC transporters. F1000Prime Rep. 2015;7:14.
   PubMedGoogle Scholar
• Wlcek K, Stieger B. ATP-binding cassette transporters in liver. Biofactors. 2014;40(2):188–198.
   PubMed Web of Science ®Google Scholar
• Burk O, Arnold KA, Nussler AK, et al. Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol Pharmacol. 2005;67(6):1954–1965.
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, et al. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92(16):1295–1302.
   PubMed Web of Science ®Google Scholar
• Ananthanarayanan M, Balasubramanian N, Makishima M, et al. Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. J Biol Chem. 2001;276(31):28857–28865.
   PubMed Web of Science ®Google Scholar
• Xu C, Luo M, Jiang H, et al. Involvement of CAR and PXR in the transcriptional regulation of CYP2B6 gene expression by ingredients from herbal medicines. Xenobiotica. 2015;45(9):773–781.
   PubMed Web of Science ®Google Scholar
• Carazo Fernández A, Smutny T, Hyrsová L, et al. Chrysin, baicalein and galangin are indirect activators of the human constitutive androstane receptor (CAR). Toxicol Lett. 2015;233(2):68–77.
   PubMed Web of Science ®Google Scholar
• Dong H, Lin W, Wu J, et al. Flavonoids activate pregnane x receptor-mediated CYP3A4 gene expression by inhibiting cyclin-dependent kinases in HepG2 liver carcinoma cells. BMC Biochem. 2010;11:23.
   PubMed Web of Science ®Google Scholar
• Li L, Stanton JD, Tolson AH, et al. Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res. 2009;26(4):872–882.
   PubMed Web of Science ®Google Scholar
• Awortwe C, Manda VK, Avonto C, et al. Echinacea purpurea up-regulates CYP1A2, CYP3A4 and MDR1 gene expression by activation of pregnane X receptor pathway. Xenobiotica. 2015;45(3):218–229.
   PubMed Web of Science ®Google Scholar
• Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev. 2004;36(1):57–104.
   PubMed Web of Science ®Google Scholar
• Prueksaritanont T, Chu X, Gibson C, et al. Drug-drug interaction studies: regulatory guidance and an industry perspective. AAPS J. 2013;15(3):629–645.
   PubMed Web of Science ®Google Scholar
• Shukla SJ, Sakamuru S, Huang R, et al. Identification of clinically used drugs that activate pregnane X receptors. Drug Metab Dispos. 2011;39(1):151–159.
   PubMed Web of Science ®Google Scholar
• Shukla SJ, Nguyen DT, Macarthur R, et al. Identification of pregnane X receptor ligands using time-resolved fluorescence resonance energy transfer and quantitative high-throughput screening. Assay Drug Dev Technol. 2009;7(2):143–169.
   PubMed Web of Science ®Google Scholar
• Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov. 2006;5(12):993–996.
   PubMed Web of Science ®Google Scholar
• Kandel BA, Ekins S, Leuner K, et al. No activation of human pregnane X receptor by hyperforin-related phloroglucinols. J Pharmacol Exp Ther. 2014;348(3):393–400.
   PubMed Web of Science ®Google Scholar
• Wan YC, Li T, Han YD, et al. Effect of pregnane xenobiotic receptor activation on inflammatory bowel disease treated with rifaximin. J Biol Regul Homeost Agents. 2015;29(2):401–410.
   PubMed Web of Science ®Google Scholar
• Lynch C, Pan Y, Li L, et al. Identification of novel activators of constitutive androstane receptor from FDA-approved drugs by integrated computational and biological approaches. Pharm Res. 2013;30(2):489–501.
   PubMed Web of Science ®Google Scholar
• Chang TK, Waxman DJ. Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev. 2006;38(1–2):51–73.
   PubMed Web of Science ®Google Scholar
• Li H, Wang H. Activation of xenobiotic receptors: driving into the nucleus. Expert Opin Drug Metab Toxicol. 2010;6(4):409–426.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang YD, Zhao P, et al. Predicting drug-drug interactions: an FDA perspective. AAPS J. 2009;11(2):300–306.
   PubMed Web of Science ®Google Scholar
• Sinz M, Kim S, Zhu Z, et al. Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab. 2006;7(4):375–388.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Kim S, Chen T, et al. Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J Biomol Screen. 2004;9(6):533–540.
   PubMed Web of Science ®Google Scholar
• Olinga P, Elferink MG, Draaisma AL, et al. Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur J Pharm Sci. 2008;33(4–5):380–389.
   PubMed Web of Science ®Google Scholar
• Huwyler J, Wright MB, Gutmann H, et al. Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin. Curr Drug Metab. 2006;7(2):119–126.
   PubMed Web of Science ®Google Scholar
• Wang YM, Lin W, Chai SC, et al. Piperine activates human pregnane X receptor to induce the expression of cytochrome P450 3A4 and multidrug resistance protein 1. Toxicol Appl Pharmacol. 2013;272(1):96–107.
   PubMed Web of Science ®Google Scholar
• Banerjee M, Chen T. Thiazide-like diuretic drug metolazone activates human pregnane X receptor to induce cytochrome 3A4 and multidrug-resistance protein 1. Biochem Pharmacol. 2014;92(2):389–402.
   PubMed Web of Science ®Google Scholar
• Pondugula SR, Flannery PC, Abbott KL, et al. Diindolylmethane, a naturally occurring compound, induces CYP3A4 and MDR1 gene expression by activating human PXR. Toxicol Lett. 2015;232(3):580–589.
   PubMed Web of Science ®Google Scholar
• Badolo L, Jensen B, Säll C, et al. Evaluation of 309 molecules as inducers of CYP3A4, CYP2B6, CYP1A2, OATP1B1, OCT1, MDR1, MRP2, MRP3 and BCRP in cryopreserved human hepatocytes in sandwich culture. Xenobiotica. 2015;45(2):177–187.
   PubMed Web of Science ®Google Scholar
• Hassan HE, Myers AL, Lee IJ, et al. Induction of xenobiotic receptors, transporters, and drug metabolizing enzymes by oxycodone. Drug Metab Dispos. 2013;41(5):1060–1069.
   PubMed Web of Science ®Google Scholar
• Hanada K, Nakai K, Tanaka H, et al. Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development. Drug Metab Pharmacokinet. 2012;27(3):301–306.
   PubMed Web of Science ®Google Scholar
• Le Vee M, Jouan E, Moreau A, et al. Regulation of drug transporter mRNA expression by interferon-γ in primary human hepatocytes. Fundam Clin Pharmacol. 2011;25(1):99–103.
   PubMed Web of Science ®Google Scholar
• Shah P, Guo T, Moore DD, et al. Role of constitutive androstane receptor in toll-like receptor-mediated regulation of gene expression of hepatic drug-metabolizing enzymes and transporters. Drug Metab Dispos. 2014;42(1):172–181.
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Ambudkar SV. Overview: ABC transporters and human disease. J Bioenerg Biomembr. 2001;33(6):453–458.
   PubMed Web of Science ®Google Scholar
• Kartenbeck J, Leuschner U, Mayer R, et al. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology. 1996;23(5):1061–1066.
   PubMed Web of Science ®Google Scholar
• van der Schoor LW, Verkade HJ, Kuipers F, et al. New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition. Expert Opin Drug Metab Toxicol. 2015;11(2):273–293.
   PubMed Web of Science ®Google Scholar
• Babeu JP, Boudreau F. Hepatocyte nuclear factor 4-alpha involvement in liver and intestinal inflammatory networks. World J Gastroenterol. 2014;20(1):22–30.
   PubMed Web of Science ®Google Scholar
• Huang W, Moriyama K, Koga T, et al. Novel mutations in ABCA1 gene in Japanese patients with Tangier disease and familial high density lipoprotein deficiency with coronary heart disease. Biochim Biophys Acta. 2001;1537(1):71–78.
   PubMed Web of Science ®Google Scholar
• Maeda K, Sugiyama Y. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet. 2008;23(4):223–235.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Balimane PV, Cho SK, et al. International transporter consortium commentary on clinically important transporter polymorphisms. Clin Pharmacol Ther. 2013;94(1):23–26.
   PubMed Web of Science ®Google Scholar
• Lang C, Meier Y, Stieger B, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics. 2007;17(1):47–60.
   PubMed Web of Science ®Google Scholar
• Haufroid V. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. Curr Drug Targets. 2011;12(5):631–646.
   PubMed Web of Science ®Google Scholar
• Yang L, Price ET, Chang CW, et al. Gene expression variability in human hepatic drug metabolizing enzymes and transporters. PLoS One. 2013 Apr 23;8(4):e60368.
   PubMed Web of Science ®Google Scholar
• Bruhn O, Cascorbi I. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol. 2014 Oct;10(10):1337–1354.
   PubMed Web of Science ®Google Scholar
• Peng L, Zhong X. Epigenetic regulation of drug metabolism and transport. Acta Pharm Sin B. 2015;5(2):106–112.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Zhong XB, Hankinson O, et al. Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport. Drug Metab Dispos. 2013;41(10):1725–1731.
   PubMed Web of Science ®Google Scholar
• Shizu R, Shindo S, Yoshida T, et al. MicroRNA-122 down-regulation is involved in phenobarbital-mediated activation of the constitutive androstane receptor. PLoS One. 2012;7(7):e41291.
   Google Scholar
• Kazantseva YA, Yarushkin AA, Mostovich LA, et al. Xenosensor CAR mediates down-regulation of miR-122 and up-regulation of miR-122 targets in the liver. Toxicol Appl Pharmacol. 2015;288(1):26–32.
   PubMed Web of Science ®Google Scholar
• Tian Y. Epigenetic regulation of pregnane X receptor activity. Drug Metab Rev. 2013;45(2):166–172.
   PubMed Web of Science ®Google Scholar
• Xie Y, Ke S, Ouyang N, et al. Epigenetic regulation of transcriptional activity of pregnane X receptor by protein arginine methyltransferase 1. J Biol Chem. 2009;284(14):9199–9205.
   PubMed Web of Science ®Google Scholar